Disclosure under Regulation 7(2) Read With Regulation 6(2) - Disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015 - Shanta Somani
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chemo Pharma Laboratories Ltd has submitted a Form C disclosure under SEBI's Prohibition of Insider Trading Regulations regarding promoter Mrs. Shanta Somani's sale of 48,781 equity shares (3.25% of paid-up capital) via off-market transaction, with trade date July 18, 2025. Pre and post-acquisition holdings are both reported at 48,781 shares (3.25%), suggesting the transaction is an inter-se transfer between promoter group entities rather than a reduction in overall promoter stake. The filing was signed by Managing Director & CEO Ruchit Mehta on July 21, 2025.
No material impact on promoter group shareholding or stock price, as the off-market nature and unchanged pre/post holdings indicate internal promoter family restructuring rather than a stake divestment to the market.